Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome-Reference-Cited by-同舟云学术

Increased PK11195-PET binding in normal-appearing white matter in clinically isolated syndrome

Published:2014-11-20 Issue:1 Volume:138 Page:110-119
ISSN:1460-2156
Container-title:Brain
language:en
Short-container-title:

Author:

Giannetti Paolo,Politis Marios,Su Paul,Turkheimer Federico E.,Malik Omar,Keihaninejad Shiva,Wu Kit,Waldman Adam,Reynolds Richard,Nicholas Richard,Piccini Paola

Publisher

Oxford University Press (OUP)

Subject

Clinical Neurology

Link

http://academic.oup.com/brain/article-pdf/138/1/110/11142098/awu331.pdf

Reference42 articles.

1. Reduced NAA-levels in the NAWM of patients with MS is a feature of progression. A study with quantitative magnetic resonance spectroscopy at 3 Tesla;Aboul-Enein;PLoS One,2010

2. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity;Banati;Brain,2000

3. Modulation of microglial/macrophage activation by macrophage inhibitory factor (TKP) or tuftsin (TKPR) attenuates the disease course of experimental autoimmune encephalomyelitis;Bhasin;BMC Immunol,2007

4. Axonal loss in normal-appearing white matter in a patient with acute MS;Bjartmar;Neurology,2001

5. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis;Brex;N Engl J Med,2002

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced Brain Imaging in Central Nervous System Demyelinating Diseases;Neuroimaging Clinics of North America;2024-08

2. Smouldering‐Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions;Annals of Neurology;2024-07-25

3. Clinical and therapeutic challenges of smouldering multiple sclerosis;Neurologia i Neurochirurgia Polska;2024-06-24

4. Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study;Multiple Sclerosis Journal;2024-03-04

5. Sex-driven variability in TSPO-expressing microglia in MS patients and healthy individuals;Frontiers in Neurology;2024-02-20